Cargando…

S105: CLONAL DIFFERENTIATION TRAJECTORIES OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA AT SINGLE CELL LEVEL

Detalles Bibliográficos
Autores principales:	Geßner, Alec, Jolly, Adrien, Sijmonsma, Tjeerd, Yu, Weijia, Abou-El-Ardat, Khalil, Kaulich, Manuel, Guenther, Stefan, Lang, Fabian, Buettner, Florian, Rieger, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428248/ http://dx.doi.org/10.1097/01.HS9.0000967332.12393.2c

Ejemplares similares

S150: TIMING AND CLONAL TRAJECTORY TO CHRONIC MYELOID LEUKAEMIA DRIVEN BY THE PHILADELPHIA CHROMOSOME
por: Kamizela, Aleksandra, et al.
Publicado: (2023)

S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Pan, Jing, et al.
Publicado: (2023)

S238: CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY
por: Loyaux, Romain, et al.
Publicado: (2023)

S143: NATURAL CLONAL EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH BIMODAL CD49D EXPRESSION REVEALS CD49D PLASTICITY
por: Tissino, Erika, et al.
Publicado: (2023)

S112: THE EFFECT OF IMMUNOGLOBULIN PROPHYLAXIS ON INFECTIOUS MORBIDITY IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS OF A RANDOMIZED CONTROLLED TRIAL
por: Thus, Kirsten, et al.
Publicado: (2023)

S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
por: Marchetti, Monia
Publicado: (2023)

S113: IMPACT OF IKZF1 DELETION IN RELAPSED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH CD19-CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
por: Cai, Zihong, et al.
Publicado: (2023)

S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY
por: Short, Nicholas, et al.
Publicado: (2023)

S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL
por: Haddad, Fadi, et al.
Publicado: (2023)

S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
por: Litzow, Mark, et al.
Publicado: (2023)

S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703
por: Wieduwilt, Matthew, et al.
Publicado: (2023)

S262: SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL), A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY
por: Roddie, Claire, et al.
Publicado: (2023)

Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic Leukemia
por: Lang, Fabian, et al.
Publicado: (2015)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
por: Ernst, Thomas, et al.
Publicado: (2023)

S114: OUTCOME OF OLDER PATIENTS (>55 YRS) WITH NEWLY DIAGNOSED PH/BCR:ABL POSITIVE ALL PROSPECTIVELY TREATED ACCORDING TO PEDIATRIC-BASED, AGE-ADAPTED GMALL PROTOCOLS
por: Lang, Fabian, et al.
Publicado: (2023)

Infections inhabituelles
Publicado: (2011)

Grippe A (H1N1) en réanimation
Publicado: (2010)

ECMO veinoveineuse
Publicado: (2013)

S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA
por: Marouf, Amira, et al.
Publicado: (2023)

S270: TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA
por: Locatelli, Franco, et al.
Publicado: (2023)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

P105 In vitro interaction of Malassezia and commensal Staphylococcus species
por: Gupta, Jyoti, et al.
Publicado: (2022)

S10.5b Bacterial and fungal coinfections in cystic fibrosis
por: Briard, Benoit
Publicado: (2022)

Full spectrum of clonal haematopoiesis‐driver mutations in chronic heart failure and their associations with mortality
por: Kiefer, Katharina C., et al.
Publicado: (2021)

Effect of Cigarette Smoking in Pregnancy on Infants Anthropometric Characteristics
por: El–Ardat, Mohammad Abou, et al.
Publicado: (2014)

O10.5. CLINICAL HIGH RISK (CHR) CRITERIA IN CHILDREN AND ADOLESCENTS NOT SUSPECTED TO DEVELOP PSYCHOSIS: NO TRANSDIAGNOSTIC SEVERITY MARKER OF MENTAL HEALTH PROBLEMS
por: Schultze-Lutter, Frauke, et al.
Publicado: (2020)

Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure
por: Dorsheimer, Lena, et al.
Publicado: (2018)

S10.5c Insight into the role of secondary metabolism in the pathogenesis of Scedosporium apiospermum
por: Papon, Nicolas, et al.
Publicado: (2022)

WS20.02 Input supporting a young person with increased cough suppression in the context of COVID-19
por: Shayle, A., et al.
Publicado: (2022)

WS05.04 SARS-CoV-2 infection is reduced in both immortalised and primary CFTR-modulated human bronchial epithelial cells
por: Lotti, V., et al.
Publicado: (2022)

WS21.03 Low-cost chain termination DNA sequencing PCR reaction to diagnose CFTR gene mutations
por: Ghani, M.U., et al.
Publicado: (2022)

WS20.06 Co-infection with Nocardia farcinia and SARS-CoV-2 causing the death of an adolescent with cystic fibrosis
por: Chapman, J., et al.
Publicado: (2022)

WS21.01 AQP5 and CFTR, two genes associated with pseudo-aquagenic palmoplantar keratoderma?
por: Girodon, E., et al.
Publicado: (2022)

S116: CELLULAR AND MOLECULAR MECHANISMS OF EVI1-EXPRESSING MLL-REARRANGED ACUTE MYELOID LEUKEMIA
por: Châtel-Soulet, Hugues-Etienne, et al.
Publicado: (2022)

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
por: Hernández-Sánchez, A., et al.
Publicado: (2022)

S131: CLINICAL IMPLICATIONS OF SECONDARY-AML TYPE MUTATIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA
por: Sun, K., et al.
Publicado: (2022)

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
por: Daver, N. G., et al.
Publicado: (2022)

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
por: Garcia-Manero, G., et al.
Publicado: (2022)

S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES
por: Meyer, E., et al.
Publicado: (2022)

S234: CLINICAL-GRADE MBIL21/4-1BBL EXPANDED NK CELLS EXHIBIT STRONGER COMPETENCE COMPARED WITH PRIMARY NK CELLS AGAINST HCMV INFECTION
por: Shang, Q.-N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lco8bm2unklc4e9p9246b57r84